- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04765150
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To develop and evaluate quantitative dynamic contrast-enhanced (DCE)-MRI analysis techniques that minimize patient- and scanner-specific variabilities in the calculation of quantitative parameters.
II. To develop and evaluate diffusion weighted imaging (DWI) methods that reduce prostate geometric distortion due to patient- and scanner-specific susceptibility and eddy current effects.
III. To develop and evaluate multi-class deep learning models that systematically integrate quantitative multi-parametric (mp)-MRI features for accurate detection and classification of clinically significant prostate cancer (csPCa).
OUTLINE:
RETROSPECTIVE: Patients' medical records are reviewed.
PROSPECTIVE: Patients undergo additional 3 Tesla (T) MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nashla Barroso
- Phone Number: (310) 794-7952
- Email: nbarroso@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA / Jonsson Comprehensive Cancer Center
-
Contact:
- Nashla Barroso
- Phone Number: 310-794-7952
- Email: nbarroso@mednet.ucla.edu
-
Principal Investigator:
- Kyung H. Sung, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male patients 18 years of age and older
- Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer
- Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)
- Ability to provide consent
Exclusion Criteria:
- Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia)
- Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent
- Prior radiotherapy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational (electronic health record review, 3 T MRI)
RETROSPECTIVE: Patients' medical records are reviewed. PROSPECTIVE: Patients undergo additional 3T MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours. |
Medical charts are reviewed
Undergo 3T MRI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of quantitative dynamic contrast (DCE)-enhanced-magnetic resonance imaging (MRI) analysis techniques
Time Frame: Up to 5 years
|
Both transfer constant (Ktrans) and rate constant (Kep) from normal prostate tissue will be evaluated for the inter-scanner variability.
Pairwise dissimilarities between distributions will be estimated by computing the Kolmogorov-Smirnov statistic, defined as the maximum difference between the empirical distribution functions over the range of the parameter, using 200 cases for each of three MRI scanners.
The mean of these pairwise dissimilarities between scanners will be computed to quantify the overall discrepancy of each DCE-MRI model.
Construction of a 95% confidence interval for the difference in the mean discrepancies using the nonparametric bootstrap will be done to compare this mean discrepancy between DCE-MRI models.
10,000 bootstrap samples will be generated by sampling patients with replacement, stratifying by the scanner.
Will conclude that the proposed DCE-MRI model has a reduced inter-scanner variability if the 95% confidence interval is entirely less than zero.
|
Up to 5 years
|
Development of diffusion weighted imaging (DWI) methods that reduce prostate geometric distortion
Time Frame: Up to 5 years
|
Differences between rectangular field of view-ENCODE and standard DWI in terms of the prostate Dice's similarity coefficient (primary outcome) and apparent diffusion coefficient consistency will be compared.
|
Up to 5 years
|
Development of multi-class deep learning models
Time Frame: Up to 5 years
|
The overall performance of FocalNet and Prostate Imaging Reporting & Data System version 2 will be compared in terms of area under the curve.
Comparison between area under the curves will be performed using DeLong's test.
Will also include the comparison between FocalNet and baseline deep learning methods (U-Net and Deeplab without focal loss [FL] and mutual finding loss [MFL]) to characterize the advantages of using FL and MFL with the same study cohort.
For each of these approaches, an optimal cut-point for classification of clinically significant prostate cancer will be identified by maximizing Youden's J (= sensitivity + specificity - 1) and will report sensitivity, specificity and 95% confidence intervals based on the selected cut-point.
|
Up to 5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kyung H Sung, PhD, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-002202 (Other Identifier: UCLA / Jonsson Comprehensive Cancer Center)
- NCI-2021-00373 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- R01CA248506 (U.S. NIH Grant/Contract)
- 441480-KS-29447 (Other Grant/Funding Number: NCI)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Carcinoma
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)UnknownCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate CarcinomaUnited States
-
University of WashingtonJanssen Research & Development, LLCTerminatedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Double-Negative Prostate CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
-
University of UtahCompletedMetastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the BoneUnited States
-
Jonsson Comprehensive Cancer CenterCompletedBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than FiftyUnited States
-
Emory UniversityCompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7United States
Clinical Trials on Electronic Health Record Review
-
M.D. Anderson Cancer CenterRecruitingRecurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingMetastatic Malignant Neoplasm in the SpineUnited States
-
Mayo ClinicCompletedMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruiting
-
Mayo ClinicExact Sciences CorporationRecruitingLynch Syndrome | Colorectal CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cancer-Associated PainUnited States
-
M.D. Anderson Cancer CenterRecruitingOvarian Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Neoplasm | Low Grade Ovarian Serous Adenocarcinoma | Primary Peritoneal Low Grade Serous Adenocarcinoma | PsammocarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingPrecision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant ChemotherapyAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Thomas Jefferson UniversityRecruitingLung CarcinomaUnited States